Search
Bumadizone
go.drugbank.com/drugs/DB13286ApprovedBumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis
Treprostinil
go.drugbank.com/drugs/DB00374ApprovedInvestigationalTreprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. … The first generic form of treprostinil became available in 2019.[A248775]
Fexapotide
go.drugbank.com/drugs/DB05493InvestigationalNX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. … Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).
Icotinib
go.drugbank.com/drugs/DB11737InvestigationalFDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US
Tildrakizumab
go.drugbank.com/drugs/DB14004ApprovedInvestigationalThe Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Iopodic acid
go.drugbank.com/drugs/DB09333ApprovedWithdrawnIopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6. Due to its particular structure, it...
Categories: Compounds used in a research, industrial, or household settingYttrium Y-90
go.drugbank.com/drugs/DB13076ApprovedInvestigationalYttrium 90 has been investigated for the treatment of Colon Cancer and Colorectal Cancer.
Mobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawn[L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic
Glycol salicylate
go.drugbank.com/drugs/DB11323ApprovedThis drug belongs to the _salicylate_ group of drugs, which are used as analgesic agents for the treatment of mild to moderate pain [L2691]. … It is found as an active ingredient and topical analgesic in patches used to provide relief for mild to moderate muscle and joint pain [L2686].
Belladonna
go.drugbank.com/drugs/DB13913Approved[DB00572] is a non-selective muscarinic antagonist that is mainly used as an adjunct for anaesthesia. … The name "belladonna" originates from the Italian words "beautiful woman" and the historical use of herb eye-drops by women to dilate the pupils of the eyes for aesthetic purposes.